Therapeutic potential and mechanism of action of oligonucleotides and ribozymes

Yan Lavrovsky; Shuo Chen; Arun K. Roy

doi:10.1006/bmme.1997.2631

Therapeutic potential and mechanism of action of oligonucleotides and ribozymes

Yan Lavrovsky, Shuo Chen, Arun K. Roy

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Specific inactivation of gene expression is an attractive approach for rational drug design to combat degenerative diseases and infectious agents. Oligonucleotide-directed triple-helix formation at cis-acting elements of gene promoters, short oligonucleotides containing base sequences that are complementary to the messenger RNA (antisense oligos), and RNA enzymes (ribozymes) that specifically cleave messenger RNA molecules are currently being used both as experimental tools and as therapeutic agents. Mechanisms of action of various oligonucleotide-based drugs, recent developments in the drug-delivery approaches, and future potentials are discussed in this review.

Original language	English (US)
Pages (from-to)	11-22
Number of pages	12
Journal	Biochemical and Molecular Medicine
Volume	62
Issue number	1
DOIs	https://doi.org/10.1006/bmme.1997.2631
State	Published - Oct 1997

ASJC Scopus subject areas

Biochemistry

Access to Document

10.1006/bmme.1997.2631

Cite this

@article{ac45d30a22e74686b91a762235bc5e40,

title = "Therapeutic potential and mechanism of action of oligonucleotides and ribozymes",

abstract = "Specific inactivation of gene expression is an attractive approach for rational drug design to combat degenerative diseases and infectious agents. Oligonucleotide-directed triple-helix formation at cis-acting elements of gene promoters, short oligonucleotides containing base sequences that are complementary to the messenger RNA (antisense oligos), and RNA enzymes (ribozymes) that specifically cleave messenger RNA molecules are currently being used both as experimental tools and as therapeutic agents. Mechanisms of action of various oligonucleotide-based drugs, recent developments in the drug-delivery approaches, and future potentials are discussed in this review.",

author = "Yan Lavrovsky and Shuo Chen and Roy, {Arun K.}",

note = "Funding Information: Studies in our laboratories are supported by NIH Grants RO3 AG14215 (Y.L.), T32 AG00165 (S.C.), RO1 AG10486 (A.K.R.) and R37 DK14744 (A.K.R.). We thank Dr. B. Chatterjee for her comments and Ms. Nyra White for secretarial assistance.",

year = "1997",

month = oct,

doi = "10.1006/bmme.1997.2631",

language = "English (US)",

volume = "62",

pages = "11--22",

journal = "Biochemical and Molecular Medicine",

issn = "1077-3150",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Therapeutic potential and mechanism of action of oligonucleotides and ribozymes

AU - Lavrovsky, Yan

AU - Chen, Shuo

AU - Roy, Arun K.

N1 - Funding Information: Studies in our laboratories are supported by NIH Grants RO3 AG14215 (Y.L.), T32 AG00165 (S.C.), RO1 AG10486 (A.K.R.) and R37 DK14744 (A.K.R.). We thank Dr. B. Chatterjee for her comments and Ms. Nyra White for secretarial assistance.

PY - 1997/10

Y1 - 1997/10

N2 - Specific inactivation of gene expression is an attractive approach for rational drug design to combat degenerative diseases and infectious agents. Oligonucleotide-directed triple-helix formation at cis-acting elements of gene promoters, short oligonucleotides containing base sequences that are complementary to the messenger RNA (antisense oligos), and RNA enzymes (ribozymes) that specifically cleave messenger RNA molecules are currently being used both as experimental tools and as therapeutic agents. Mechanisms of action of various oligonucleotide-based drugs, recent developments in the drug-delivery approaches, and future potentials are discussed in this review.

AB - Specific inactivation of gene expression is an attractive approach for rational drug design to combat degenerative diseases and infectious agents. Oligonucleotide-directed triple-helix formation at cis-acting elements of gene promoters, short oligonucleotides containing base sequences that are complementary to the messenger RNA (antisense oligos), and RNA enzymes (ribozymes) that specifically cleave messenger RNA molecules are currently being used both as experimental tools and as therapeutic agents. Mechanisms of action of various oligonucleotide-based drugs, recent developments in the drug-delivery approaches, and future potentials are discussed in this review.

UR - http://www.scopus.com/inward/record.url?scp=0031259504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031259504&partnerID=8YFLogxK

U2 - 10.1006/bmme.1997.2631

DO - 10.1006/bmme.1997.2631

M3 - Review article

C2 - 9367793

AN - SCOPUS:0031259504

SN - 1077-3150

VL - 62

SP - 11

EP - 22

JO - Biochemical and Molecular Medicine

JF - Biochemical and Molecular Medicine

IS - 1

ER -

Therapeutic potential and mechanism of action of oligonucleotides and ribozymes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this